_MACHINE TRANSLATION_
The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to Current Report No. 25/2026 dated 15 July 2026, hereby informs that due to the inclusion in the report of an additional attachment No. 3 containing the Updated Proxy Voting Form in .docx format, Current Report No. 25/2026 received a negative technical validation result within the framework of the European Single Access Point (ESAP) platform established pursuant to Regulation (EU) 2023/2859 of the European Parliament and of the Council of 13 December 2023.
In addition, Attachments No. 2 and No. 3, i.e. the Updated Draft Resolutions for the Ordinary General Meeting of Shareholders and the Updated Proxy Voting Form, contain display errors in references to individual sections and paragraphs indicated in Draft Resolution No. 21/06/2026, resulting from an incorrect conversion of the files into .pdf format.
At the same time, the Management Board of the Issuer informs that the draft resolutions included in Attachment No. 1 are correct and that all other information contained in the above-mentioned current report remains unchanged.
Accordingly, the Management Board of the Issuer hereby republishes the full content of Current Report No. 25/2026 together with the corrected draft of Resolution No. 21/06/2026 in Attachments No. 2 and No. 3, and without the Updated Proxy Voting Form in .docx format:
“The Management Board of Bioceltix S.A. with its registered office in Wrocław (the ‘Issuer’ or the ‘Company’) hereby announces that it has received from a shareholder representing at least one-twentieth of the Company’s share capital, namely TOTAL Closed-End Investment Fund (TOTAL Fundusz Inwestycyjny Zamknięty), a submission of draft resolutions pursuant to Article 401 § 4 of the Polish Commercial Companies Code concerning items 17 and 18 of the planned agenda of the Ordinary General Meeting of Shareholders of the Issuer, as adopted on 23 June 2026 and described in detail in Current Report No. 18/2026, i.e. a resolution regarding the establishment of an Incentive Programme at the Company and the repeal of Resolution No. 05/02/2021 of the Extraordinary General Meeting of the Company dated 9 February 2021, as amended by Resolution No. 19/06/2024 of the Ordinary General Meeting of the Company dated 26 June 2024, as well as a resolution regarding the issue of Series A registered subscription warrants with the exclusion of pre-emptive rights of existing shareholders, the conditional increase of the Company’s share capital through the issue of Series H ordinary bearer shares with the exclusion of pre-emptive rights of existing shareholders, the repeal of Resolution No. 03/02/2021 and Resolution No. 04/02/2021 of the Extraordinary General Meeting of the Company dated 9 February 2021, and the related amendment to the Company’s Articles of Association, which Ordinary General Meeting of Shareholders is to be continued following an adjournment on 16 July 2026.
The content of the shareholder’s request, as well as the updated draft resolutions proposed for adoption by the Ordinary General Meeting of Shareholders of the Issuer and the updated proxy voting form, are attached to this current report and have been published on the Company’s website at: https://bioceltix.com/ir/walne-zgromadzenia/ in accordance with Article 402(3) of the Polish Commercial Companies Code.
Detailed legal basis: § 20(1)(4) of the Regulation of the Minister of Finance of 6 June 2025 on current and periodic information to be disclosed by issuers of securities and on conditions for recognizing as equivalent information required under the laws of a non-member state.”
Attachments:
– Żądanie akcjonariusza wraz z projektami uchwał,
– Zaktualizowane projekty uchwał na Zwyczajne Walne Zgromadzenie,
– Zaktualizowany formularz głosowania przez pełnomocnika.
Signatures of persons representing the Company:
Łukasz Bzdzion – President of the Management Board
Paweł Wielgus – Member of the Management Board